FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3172679188> ?p ?o ?g. }

• W3172679188 endingPage "S071" @default.
• W3172679188 startingPage "S070" @default.
• W3172679188 abstract "Abstract Background Crohn’s disease (CD) can develop fistulizing complications at any time during the disease course. Enterocutaneous fistulas (ECF) are disabling lesions with a significant impact on quality of life. The aim of this study was to describe the characteristics and natural history of ECF complicating CD, and to analyze its medical and/or surgical management. Methods A retrospective analysis of all adult patients with fistulizing CD with at least one episode of ECF from the ENEIDA registry (over 68,000 patients) was performed. ECF were defined as a communication between the gastrointestinal tract and the skin producing leakage of luminal contents. Additional data describing the ECF and its medical or surgical management were gathered. The main endpoint was any ECF-related surgical intervention. Fistula closure was defined as the absence of drainage, with no new abscess or surgery for at least 6 months. A comparison of the characteristics and outcomes after the availability of biologic agents (Jan/2000) was also performed. The baseline characteristics were analyzed by means of descriptive statistics and were compared by non-parametric tests. Factors associated with surgery were further evaluated in a binary multivariable regression and survival analysis. Results A total of 301 ECF in 286 patients from 46 hospitals diagnosed between Jan/1970-Sept/2020 were included (median age 34 years (IQR, 27–46); 59% male; 67% L3). ECF had a median of 1 external opening (range 1–10), 59% with concomitant internal fistulas, and usually involved the ileum (67%) or colon (23%). After 146 months (IQR, 69–233) of follow-up, 37% received thiopurines, 40% anti-TNF, 6% ustekinumab and 2% vedolizumab. Surgery was performed in 208 patients (69%) after a median of 4 months (IQR, 1.4–12). Fistula closure was achieved in 253 patients (84%) after 30 months (IQR, 4–84), mostly after surgery (54%) and in one third after medical therapy. Fistula recurrence was uncommon (11%) after closure. Patient and fistula characteristics were significantly different after the availability of biologics. In fact, anti-TNF biologics and thiopurines reduced surgery risk (HR 0.5; 0.38–0.67; HR 0.64; 0.47–0.86, respectively). The surgery rate in the biologic era tends to be lower than before (OR 0.63;0.33–1.09) while timing is similar. Closure rates are also comparable, but it was obtained more frequently after medical therapy once biologicals were available (OR 2.21; 1.13–4.29). Conclusion ECF complicating CD entail a high burden of medical and surgical resources. Closure rates are high, usually after surgery, and fistula recurrence is uncommon. A number of patients can benefit from medical therapy and achieve fistula closure." @default.
• W3172679188 created "2021-06-22" @default.
• W3172679188 creator A5000807154 @default.
• W3172679188 creator A5002259935 @default.
• W3172679188 creator A5007504791 @default.
• W3172679188 creator A5011686504 @default.
• W3172679188 creator A5015851440 @default.
• W3172679188 creator A5017557984 @default.
• W3172679188 creator A5019026198 @default.
• W3172679188 creator A5019990518 @default.
• W3172679188 creator A5022657722 @default.
• W3172679188 creator A5031184196 @default.
• W3172679188 creator A5033282443 @default.
• W3172679188 creator A5034884892 @default.
• W3172679188 creator A5037542727 @default.
• W3172679188 creator A5042351557 @default.
• W3172679188 creator A5042665707 @default.
• W3172679188 creator A5045113191 @default.
• W3172679188 creator A5046789127 @default.
• W3172679188 creator A5047285332 @default.
• W3172679188 creator A5050136128 @default.
• W3172679188 creator A5050705694 @default.
• W3172679188 creator A5052366621 @default.
• W3172679188 creator A5053104917 @default.
• W3172679188 creator A5053129179 @default.
• W3172679188 creator A5053794814 @default.
• W3172679188 creator A5056264715 @default.
• W3172679188 creator A5056652716 @default.
• W3172679188 creator A5057350010 @default.
• W3172679188 creator A5058442099 @default.
• W3172679188 creator A5064167457 @default.
• W3172679188 creator A5075117607 @default.
• W3172679188 creator A5077137875 @default.
• W3172679188 creator A5077550825 @default.
• W3172679188 creator A5081680541 @default.
• W3172679188 creator A5083953774 @default.
• W3172679188 creator A5084079496 @default.
• W3172679188 creator A5084337079 @default.
• W3172679188 creator A5088596171 @default.
• W3172679188 creator A5089006129 @default.
• W3172679188 creator A5089370063 @default.
• W3172679188 creator A5089418535 @default.
• W3172679188 date "2021-05-01" @default.
• W3172679188 modified "2023-10-18" @default.
• W3172679188 title "DOP32 Long-term outcomes of enterocutaneous fistula complicating Crohn’s Disease: The ECUFIT study from GETECCU" @default.
• W3172679188 doi "https://doi.org/10.1093/ecco-jcc/jjab073.071" @default.
• W3172679188 hasPublicationYear "2021" @default.
• W3172679188 type Work @default.
• W3172679188 sameAs 3172679188 @default.
• W3172679188 citedByCount "0" @default.
• W3172679188 crossrefType "journal-article" @default.
• W3172679188 hasAuthorship W3172679188A5000807154 @default.
• W3172679188 hasAuthorship W3172679188A5002259935 @default.
• W3172679188 hasAuthorship W3172679188A5007504791 @default.
• W3172679188 hasAuthorship W3172679188A5011686504 @default.
• W3172679188 hasAuthorship W3172679188A5015851440 @default.
• W3172679188 hasAuthorship W3172679188A5017557984 @default.
• W3172679188 hasAuthorship W3172679188A5019026198 @default.
• W3172679188 hasAuthorship W3172679188A5019990518 @default.
• W3172679188 hasAuthorship W3172679188A5022657722 @default.
• W3172679188 hasAuthorship W3172679188A5031184196 @default.
• W3172679188 hasAuthorship W3172679188A5033282443 @default.
• W3172679188 hasAuthorship W3172679188A5034884892 @default.
• W3172679188 hasAuthorship W3172679188A5037542727 @default.
• W3172679188 hasAuthorship W3172679188A5042351557 @default.
• W3172679188 hasAuthorship W3172679188A5042665707 @default.
• W3172679188 hasAuthorship W3172679188A5045113191 @default.
• W3172679188 hasAuthorship W3172679188A5046789127 @default.
• W3172679188 hasAuthorship W3172679188A5047285332 @default.
• W3172679188 hasAuthorship W3172679188A5050136128 @default.
• W3172679188 hasAuthorship W3172679188A5050705694 @default.
• W3172679188 hasAuthorship W3172679188A5052366621 @default.
• W3172679188 hasAuthorship W3172679188A5053104917 @default.
• W3172679188 hasAuthorship W3172679188A5053129179 @default.
• W3172679188 hasAuthorship W3172679188A5053794814 @default.
• W3172679188 hasAuthorship W3172679188A5056264715 @default.
• W3172679188 hasAuthorship W3172679188A5056652716 @default.
• W3172679188 hasAuthorship W3172679188A5057350010 @default.
• W3172679188 hasAuthorship W3172679188A5058442099 @default.
• W3172679188 hasAuthorship W3172679188A5064167457 @default.
• W3172679188 hasAuthorship W3172679188A5075117607 @default.
• W3172679188 hasAuthorship W3172679188A5077137875 @default.
• W3172679188 hasAuthorship W3172679188A5077550825 @default.
• W3172679188 hasAuthorship W3172679188A5081680541 @default.
• W3172679188 hasAuthorship W3172679188A5083953774 @default.
• W3172679188 hasAuthorship W3172679188A5084079496 @default.
• W3172679188 hasAuthorship W3172679188A5084337079 @default.
• W3172679188 hasAuthorship W3172679188A5088596171 @default.
• W3172679188 hasAuthorship W3172679188A5089006129 @default.
• W3172679188 hasAuthorship W3172679188A5089370063 @default.
• W3172679188 hasAuthorship W3172679188A5089418535 @default.
• W3172679188 hasConcept C126322002 @default.
• W3172679188 hasConcept C141071460 @default.
• W3172679188 hasConcept C167135981 @default.
• W3172679188 hasConcept C2776341189 @default.
• W3172679188 hasConcept C2777035434 @default.
• W3172679188 hasConcept C2779105634 @default.
• W3172679188 hasConcept C2779134260 @default.

• next